Loading...
CDLX logo

Cardlytics, Inc.NasdaqGM:CDLX Rapport sur les actions

Capitalisation boursière US$35.2m
Prix de l'action
US$0.65
US$1.04
37.3% sous-évalué décote intrinsèque
1Y-70.0%
7D-26.0%
Valeur du portefeuille
Voir

Cardlytics, Inc.

NasdaqGM:CDLX Rapport sur les actions

Capitalisation boursière : US$35.2m

Cardlytics (CDLX) Aperçu de l'action

Cardlytics, Inc. exploite une plateforme publicitaire aux États-Unis et au Royaume-Uni. Plus de détails

CDLX analyse fondamentale
Score flocon de neige
Évaluation2/6
Croissance future0/6
Performances passées0/6
Santé financière2/6
Dividendes0/6

CDLX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Cardlytics, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 Cardlytics
Historique des cours de bourse
Prix actuel de l'actionUS$0.65
Plus haut sur 52 semainesUS$3.28
Plus bas sur 52 semainesUS$0.57
Bêta0.69
Variation sur 1 mois-27.38%
Variation sur 3 mois-30.09%
Variation sur 1 an-70.00%
Variation sur 3 ans-88.62%
Variation sur 5 ans-99.28%
Évolution depuis l'introduction en bourse-95.13%

Nouvelles et mises à jour récentes

Article d'analyse 21h

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
Mise à jour de l'analyse May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
Mise à jour de l'analyse Apr 17

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.
Mise à jour de l'analyse Apr 03

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.

Recent updates

Article d'analyse 21h

Cardlytics, Inc. (NASDAQ:CDLX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Cardlytics, Inc. ( NASDAQ:CDLX ) just released its latest first-quarter results and things are looking bullish...
Mise à jour de l'analyse May 01

CDLX: Reset Expectations And Banking Partner Shifts Will Drive Future Repricing

Analysts have nudged Cardlytics' average price target lower to about $1, with cuts from $2 to $1 and from $1.50 to $1.25. These changes reflect updated views after Q4 results, Q1 guidance, and the expected impact of the BofA exit and Bridg divestiture.
Mise à jour de l'analyse Apr 17

CDLX: Reset Guidance And BofA Exit Will Drive Upside Potential

Narrative Update on Cardlytics Analysts have cut their Cardlytics price targets to a range of about $1 to $1.25, citing Q1 guidance that resets expectations following the Bank of America exit and Bridg divestiture and leaves the stock in what they describe as "show me" territory. Analyst Commentary Recent research updates underline that Q1 guidance and the effects of the Bank of America exit and Bridg divestiture are central to how analysts are framing Cardlytics today.
Mise à jour de l'analyse Apr 03

CDLX: Reset Expectations And Partner Changes Will Shape Future Repricing

Analysts have trimmed Cardlytics' implied fair value from about $1.29 to roughly $1.04. This reflects recent price target cuts to $1 and $1.25 as they factor in softer revenue expectations and the impact of the BofA exit and Bridg divestiture.
Mise à jour de l'analyse Mar 20

CDLX: Reset Guidance And One Bank Exit Will Define Upside Potential

Narrative update on Cardlytics Analysts have trimmed Cardlytics' implied fair value from about $2.00 to roughly $1.25, reflecting lower price targets around $1.00 to $1.25 after Q1 guidance reset expectations for revenue trends, margins and future P/E as the business adjusts to the BofA exit and Bridg divestiture. Analyst Commentary Recent Street research has centered on recalibrated price targets around Q1 guidance and the operational impact of the BofA exit and Bridg divestiture.
Mise à jour de l'analyse Mar 06

CDLX: Reset Expectations And CFO Return Will Support Future Rerating

Analysts have trimmed their Cardlytics price target from $1.50 to $1.25, reflecting updated assumptions around fair value, revenue trends, and profitability following recent guidance resets and business changes. Analyst Commentary Recent commentary around the reduced US$1.25 price target centers on how quickly Cardlytics can adjust to its updated outlook and business mix after the Q1 guidance reset, the BofA exit, and the Bridg divestiture.
Article d'analyse Jan 08

Cardlytics, Inc. (NASDAQ:CDLX) Stock Catapults 30% Though Its Price And Business Still Lag The Industry

Those holding Cardlytics, Inc. ( NASDAQ:CDLX ) shares would be relieved that the share price has rebounded 30% in the...
Seeking Alpha Oct 06

Cardlytics: Debt Overhang Casts Shadow On Upside

Summary Cardlytics is dealing with a significant headwind in Q3 due to restrictions from its largest bank partner. CDLX sold off sharply following Q2 results, but has since rallied following a bullish report from Citron Research. Management is targeting positive FCF through growth with its newest large bank partner while also substantially lowering operating expenses. Debt remains the biggest risk, though the earliest maturity is not until April 2028. I remain cautious until I see evidence of sequential growth and improving cash burn. Read the full article on Seeking Alpha
Mise à jour de l'analyse Aug 08

Bank Partnerships And Data-Driven Marketing Will Shape Future Markets

The notable downward revision in Cardlytics’ price target reflects sharply reduced revenue growth forecasts and a higher discount rate, resulting in a new consensus fair value of $2.10. What's in the News Cardlytics provided Q3 2025 revenue guidance of $52.2 million to $58.2 million.
Article d'analyse Jul 23

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX) As Its Stock Soars 64%

Cardlytics, Inc. ( NASDAQ:CDLX ) shares have continued their recent momentum with a 64% gain in the last month alone...
Article d'analyse Jul 05

Is Cardlytics (NASDAQ:CDLX) Using Debt Sensibly?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d'analyse May 29

Cardlytics, Inc. (NASDAQ:CDLX) Soars 30% But It's A Story Of Risk Vs Reward

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 30% in the...
Article d'analyse Apr 07

Why Investors Shouldn't Be Surprised By Cardlytics, Inc.'s (NASDAQ:CDLX) 30% Share Price Plunge

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 30% in the last thirty...
User avatar
Nouvelle analyse Apr 03

US Neobank And Taiwan Office Will Unlock New Markets

Expansion into new sectors and partnerships with financial institutions and neobanks is expected to diversify the customer base and boost revenue.
Article d'analyse Mar 11

Cardlytics (NASDAQ:CDLX) Has Debt But No Earnings; Should You Worry?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Article d'analyse Feb 21

Revenues Tell The Story For Cardlytics, Inc. (NASDAQ:CDLX)

It's not a stretch to say that Cardlytics, Inc.'s ( NASDAQ:CDLX ) price-to-sales (or "P/S") ratio of 0.5x right now...
Seeking Alpha Feb 13

Cardlytics: Short-Term Headwinds Drive Long-Term Success

Summary Cardlytics, Inc. offers an asymmetric investment opportunity for those who can handle stock price volatility and slow business progress. Recent issues with ad deliveries have impacted revenue and market sentiment but positioned the company for long-term success. The shift to engagement-based pricing is expected to drive broader platform adoption. Trading at just 0.51x P/S and 1.10x EV/Revenue, Cardlytics presents significant upside potential from current valuations. Amex Partnership could add $600 million in market value based on $35 million in incremental EBITDA for 2025. Read the full article on Seeking Alpha
Article d'analyse Jan 10

At US$3.35, Is It Time To Put Cardlytics, Inc. (NASDAQ:CDLX) On Your Watch List?

Cardlytics, Inc. ( NASDAQ:CDLX ), might not be a large cap stock, but it saw significant share price movement during...
Seeking Alpha Dec 07

Cardlytics Continues Revenue Contraction Amid Worsening Economics

Summary Cardlytics, Inc. beat revenue and earnings estimates, but faces declining unit economics and revenue stabilization challenges. The AdTech market is projected to grow significantly, yet CDLX struggles with delivery inefficiencies, declining ARPU, and advertiser hesitancy, impacting its financial performance. Recent financial trends show falling revenue, negative operating income, and high stock-based compensation, with significant cash burn and a 52.1% stock price decline over the past year. Management's turnaround efforts may take several quarters, with increased R&D spending expected to further negatively affect operating results. My outlook on CDLX is to sell. Read the full article on Seeking Alpha
Article d'analyse Nov 23

Estimating The Intrinsic Value Of Cardlytics, Inc. (NASDAQ:CDLX)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Cardlytics fair value estimate is US$3.50 Current share price...
Article d'analyse Nov 05

After Leaping 27% Cardlytics, Inc. (NASDAQ:CDLX) Shares Are Not Flying Under The Radar

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders are no doubt pleased to see that the share price has bounced 27% in the...
Article d'analyse Oct 15

Is Cardlytics (NASDAQ:CDLX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha Sep 17

Cardlytics: Execution Risks Are Elevated, But Reasons For Optimism Remain (Maintain Hold Rating)

Summary Shares have fallen nearly 50% since the Q2 earnings report, which came in well below management’s guidance. With Q3 guidance pointing to further weakness, the company’s financial health hinges on management’s execution towards solving the ongoing issues on its ads platform. Assuming no additional setbacks, the company should return to growth next year and generate positive FCF. While risks remain high, the current valuation is undemanding, leading me to maintain a Neutral rating. Read the full article on Seeking Alpha
Article d'analyse Aug 09

Cardlytics, Inc.'s (NASDAQ:CDLX) 63% Share Price Plunge Could Signal Some Risk

Cardlytics, Inc. ( NASDAQ:CDLX ) shareholders that were waiting for something to happen have been dealt a blow with a...
Seeking Alpha Jul 02

Cardlytics: Has Multiple Potential Growth Levers, But Persistent Risks Remain

Summary Cardlytics shares have declined significantly after Q1 earnings came in below management’s guidance. Key metrics show that the business is performing well. Recent steps taken by management have extended its debt until 2029, leaving the company in a more stable financial position. CDLX has multiple growth levers and significant risks that investors should consider. Read the full article on Seeking Alpha
Article d'analyse May 31

Cardlytics, Inc.'s (NASDAQ:CDLX) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors

The Cardlytics, Inc. ( NASDAQ:CDLX ) share price has softened a substantial 30% over the previous 30 days, handing back...
Seeking Alpha Apr 17

The Power Of Cardlytics' Data Partnerships Including Bank of America

Summary Cardlytics recently appointed Liane Hornsey to its Board of Directors, which could attract new investors and accelerate hiring and productivity. The company offers a suite of solutions for advertising, marketing, and customer engagement through its own mobile application and partnerships with financial institutions. Future growth projects, synergies, database integration, and new partnerships have the potential to drive net sales growth and increase investor attention. Read the full article on Seeking Alpha
Article d'analyse Apr 10

Cardlytics, Inc.'s (NASDAQ:CDLX) 81% Jump Shows Its Popularity With Investors

Despite an already strong run, Cardlytics, Inc. ( NASDAQ:CDLX ) shares have been powering on, with a gain of 81% in the...
Seeking Alpha Feb 16

Cardlytics: Good Prospects But Macro Uncertain

Summary Cardlytics has access to 50% of card swipe data through its relationships with major US consumer banks. The company's acquisitions of Dosh and Bridg have strengthened and diversified its platform. The impact of macroeconomic factors on consumer spending and advertising budgets may constrain Cardlytics' growth in the short to medium term. Read the full article on Seeking Alpha
Article d'analyse Jan 18

Cardlytics, Inc.'s (NASDAQ:CDLX) 29% Share Price Plunge Could Signal Some Risk

Unfortunately for some shareholders, the Cardlytics, Inc. ( NASDAQ:CDLX ) share price has dived 29% in the last thirty...
Article d'analyse Jan 04

Would Cardlytics (NASDAQ:CDLX) Be Better Off With Less Debt?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Article d'analyse Oct 05

We Think Cardlytics (NASDAQ:CDLX) Has A Fair Chunk Of Debt

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Rendement pour les actionnaires

CDLXUS MediaUS Marché
7D-26.0%-0.6%2.6%
1Y-70.0%-17.7%26.2%

Rendement vs Industrie: CDLX a sous-performé le secteur US Media qui a rapporté -17.7 % au cours de l'année écoulée.

Rendement vs marché: CDLX a sous-performé le marché US qui a rapporté 26.2 % au cours de l'année écoulée.

Volatilité des prix

Is CDLX's price volatile compared to industry and market?
CDLX volatility
CDLX Average Weekly Movement14.3%
Media Industry Average Movement9.1%
Market Average Movement7.2%
10% most volatile stocks in US Market16.1%
10% least volatile stocks in US Market3.2%

Cours de l'action stable: Le cours de l'action de CDLX a été volatil au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de CDLX a diminué de 22% à 14% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.

À propos de l'entreprise

FondéeSalariésPDGSite web
2008275Amit Guptawww.cardlytics.com

Cardlytics, Inc. exploite une plateforme publicitaire aux États-Unis et au Royaume-Uni. La société propose la plateforme Cardlytics, un canal publicitaire bancaire natif exclusif qui permet aux spécialistes du marketing d'atteindre les clients par le biais de canaux numériques, tels que l'Internet, les applications mobiles, le courrier électronique et diverses notifications en temps réel ; et la plateforme Bridg, une plateforme de données sur les clients qui utilise les données des points de vente provenant des partenaires de données des commerçants, y compris les données d'achat au niveau des produits pour permettre aux spécialistes du marketing d'effectuer des analyses et un marketing de fidélisation ciblé, ainsi que de mesurer l'impact de leurs activités de marketing. Cardlytics, Inc. a été créée en 2008 et son siège social se trouve à Atlanta, en Géorgie.

Cardlytics, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de Cardlytics se comparent-ils à sa capitalisation boursière ?
CDLX statistiques fondamentales
Capitalisation boursièreUS$35.25m
Bénéfices(TTM)-US$106.97m
Recettes(TTM)US$211.16m
0.2x
Ratio P/S
-0.3x
Ratio P/E

Le site CDLX est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
CDLX compte de résultat (TTM)
RecettesUS$211.16m
Coût des recettesUS$110.95m
Marge bruteUS$100.21m
Autres dépensesUS$207.18m
Les revenus-US$106.97m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-1.94
Marge brute47.46%
Marge bénéficiaire nette-50.66%
Ratio dettes/capitaux propres-5,101.2%

Quelles ont été les performances à long terme de CDLX?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/11 05:09
Cours de l'action en fin de journée2026/05/11 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

Cardlytics, Inc. est couverte par 12 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Omar DessoukyBofA Global Research
Jason KreyerCraig-Hallum Capital Group LLC
Robert CoolbrithEvercore ISI